2018 Abstract Categories
Please review the abstract categories below before submitting an abstract for the 2018 ASH Meeting on Lymphoma Biology.
back to top
- Genetic Mechanisms Underlying Lymphomagenesis
Includes genetic driven mechanisms of pathogenesis involving lymphoid malignancies and encompasses recurrent somatic mutations and/or copy number alterations as well as heritable variation associated with lymphoma risk.
- Epigenetic Mechanisms in Leukemia and Lymphoma
Includes epigenetic mechanisms that underlie leukemia and lymphoma pathogenesis and/or alterations to chromatic remodeling that contribute to lymphoma initiation and/or progression.
- Cell of Origin, Tumor Heterogeneity, and Microenvironmental Interactions
Includes studies that focus on tumor clonal development, evolution, and intra-tumoral cellular heterogeneity involving infiltrating cells in lymphoid malignancies as well as novel strategies to dynamically and non-invasively monitor such evolution. This category also includes studies investigating the role of the tumor microenvironment in tumor biology and pathogenesis.
- Signaling Pathways in Leukemia and Lymphoma
Includes primarily basic studies of signaling pathways associated with lymphomagenesis. Includes studies of the role of post-translational receptor modification, oncogenes, and tumor suppressor genes in cellular and mouse models as well as patients.
- Targeting Cell Survival
Includes studies aimed at molecular understanding of essential survival pathways in lymphoma, including strategies for targeted therapeutic regimens.
- Immunotherapies for Lymphoid Cancers
Includes studies employing novel therapies that target aspects of adaptive and innate immunity as part of their mechanism of action.
- Biological and Targeted Therapies in Lymphoid Malignancies
Includes novel targeted treatment approaches to lymphoid malignancies, such as mechanism-based combination strategies, excluding immunotherapies.
- T-Cell Lymphomas and Rare Entities
Includes primarily basic studies of T-cell lymphoproliferative diseases, lymphomas of infectious etiology, and other rare entities.